PL3959213T3 - Pirymidynowe inhibitory JAK w leczeniu chorób skóry - Google Patents

Pirymidynowe inhibitory JAK w leczeniu chorób skóry

Info

Publication number
PL3959213T3
PL3959213T3 PL20727424.2T PL20727424T PL3959213T3 PL 3959213 T3 PL3959213 T3 PL 3959213T3 PL 20727424 T PL20727424 T PL 20727424T PL 3959213 T3 PL3959213 T3 PL 3959213T3
Authority
PL
Poland
Prior art keywords
pyrimidine
treatment
skin diseases
jak inhibitors
jak
Prior art date
Application number
PL20727424.2T
Other languages
English (en)
Polish (pl)
Inventor
Philip A. GERKEN
Jianhua Chao
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of PL3959213T3 publication Critical patent/PL3959213T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20727424.2T 2019-04-24 2020-04-23 Pirymidynowe inhibitory JAK w leczeniu chorób skóry PL3959213T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837827P 2019-04-24 2019-04-24
PCT/US2020/029466 WO2020219640A1 (en) 2019-04-24 2020-04-23 Pyrimidine jak inhibitors for the treatment of skin diseases

Publications (1)

Publication Number Publication Date
PL3959213T3 true PL3959213T3 (pl) 2024-11-04

Family

ID=70779856

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20727424.2T PL3959213T3 (pl) 2019-04-24 2020-04-23 Pirymidynowe inhibitory JAK w leczeniu chorób skóry

Country Status (11)

Country Link
US (1) US11439641B2 (https=)
EP (1) EP3959213B1 (https=)
JP (1) JP7482152B2 (https=)
AR (1) AR118767A1 (https=)
CA (1) CA3135388A1 (https=)
ES (1) ES2994097T3 (https=)
HR (1) HRP20241053T1 (https=)
HU (1) HUE067909T2 (https=)
PL (1) PL3959213T3 (https=)
TW (1) TW202106681A (https=)
WO (1) WO2020219640A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001706RA (en) 2017-10-27 2020-03-30 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
PL3958969T3 (pl) 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2022094174A1 (en) * 2020-10-30 2022-05-05 Children's Hospital Medical Center Compositions and methods for the treatment of esophageal conditions
JP2024516299A (ja) * 2021-05-03 2024-04-12 インサイト・コーポレイション 結節性痒疹の治療のためのルキソリチニブ
UA129643C2 (uk) 2021-05-03 2025-06-18 Інсайт Корпорейшн Інгібітори шляху jak1 для лікування вузлуватого свербця
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20070179125A1 (en) 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2015094803A1 (en) 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (https=) 2014-08-21 2018-03-31
ES2753159T3 (es) 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
SG11202001706RA (en) 2017-10-27 2020-03-30 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
WO2020108516A1 (zh) 2018-11-27 2020-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
WO2020108613A1 (zh) 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
PL3958969T3 (pl) * 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
CN113372364B (zh) 2020-03-10 2024-05-31 明慧医药(上海)有限公司 一类jak激酶抑制剂及其制备和应用
CN113372351A (zh) 2020-03-10 2021-09-10 明慧医药(杭州)有限公司 一类jak激酶抑制剂及其制备和应用

Also Published As

Publication number Publication date
EP3959213A1 (en) 2022-03-02
TW202106681A (zh) 2021-02-16
ES2994097T3 (en) 2025-01-17
JP7482152B2 (ja) 2024-05-13
CA3135388A1 (en) 2020-10-29
HUE067909T2 (hu) 2024-11-28
US20200338073A1 (en) 2020-10-29
AR118767A1 (es) 2021-10-27
WO2020219640A1 (en) 2020-10-29
JP2022529371A (ja) 2022-06-21
EP3959213C0 (en) 2024-06-05
EP3959213B1 (en) 2024-06-05
US11439641B2 (en) 2022-09-13
HRP20241053T1 (hr) 2024-11-08

Similar Documents

Publication Publication Date Title
PL3959213T3 (pl) Pirymidynowe inhibitory JAK w leczeniu chorób skóry
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL276383A (en) Treatment of ophthalmological diseases
IL288523A (en) Compounds for the treatment of pd-l1 diseases
IL279260A (en) KDM1A inhibitors for the treatment of diseases
ES3064674T3 (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL282643A (en) Soft combinations for the treatment of hematological diseases
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3744347A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES
SG11202006374VA (en) Treatment of demyelinating diseases
IL282360A (en) Treatment for neurological diseases
PT3603621T (pt) Lipossomas para o tratamento de doenças oculares
IL291146A (en) Treatment of hidradenitis with jak inhibitors
EP3883567B8 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
ZA202106250B (en) Therapeutic uses of dulaglutide
HUE069820T2 (hu) Nalfurafin alkalmazása demielinizációs betegségek kezelésére
PT3833378T (pt) Tratamento de verrugas
CA3266235A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES
GB202015959D0 (en) Treatment of diseases involving NAD
EP3755334A4 (en) TREATMENT OF LIVER DISEASES
GB201909438D0 (en) Treatment of diseases
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
EP4037689A4 (en) 18-MC ON SUBSTANCE ABUSE TREATMENT
ZA201904327B (en) Treatment of skin conditions